How has Sarepta Therapeutics, Inc.'s other noncash income (expense) changed year-over-year?

Sarepta Therapeutics, Inc.'s other noncash income (expense) increased by 176.1% year-over-year, from -$1.69M to $1.29M.

Sarepta Therapeutics, Inc. SRPT Other Noncash Income (Expense)

PfizerPFE

——

BioMarin PharmaceuticalsBMRN

——

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Market cap$1.76B-63.1%

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Sarepta Therapeutics, Inc.'s other noncash income (expense)?: Sarepta Therapeutics, Inc. (SRPT) reported other noncash income (expense) of $1.29M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s other noncash income (expense) changed year-over-year?: Sarepta Therapeutics, Inc.'s other noncash income (expense) increased by 176.1% year-over-year, from -$1.69M to $1.29M.